Benefits of Pediatric Obesity Treatment Endure Into Young Adulthood
By Lori Solomon HealthDay Reporter
TUESDAY, Jan. 28, 2025 -- A positive response to treatment for pediatric obesity has enduring health benefits into young adulthood, according to a study published online Jan. 21 in JAMA Pediatrics.
Resthie R. Putri, Ph.D., from the Karolinska Institutet in Stockholm, and colleagues examined the long-term effect of different responses to pediatric obesity treatment on critical health outcomes in young adulthood. The analysis included 6,713 participants in the Swedish Childhood Obesity Treatment Register (aged 6 to 17 years at baseline) who were receiving at least one year of obesity treatment and followed until 18 to 30 years.
The researchers found that the median age at obesity treatment initiation was 12.1 years, and treatment duration was 3.0 years. Unadjusted incidence rates of type 2 diabetes, hypertension, dyslipidemia, weight-loss bariatric surgery, and depression or anxiety outcomes tended to decrease with better treatment response but were still higher than the general population. Obesity remission or a good response in obesity treatment was associated with a reduced risk for mortality (adjusted hazard ratio [HR], 0.12) compared with poor response. There was also an association between good response and a lower risk for type 2 diabetes (HR, 0.42), dyslipidemia (HR, 0.31), and bariatric surgery (HR, 0.42). Similar findings were seen for obesity remission, which was also associated with a lower risk for hypertension (HR, 0.40). There was no association seen between treatment response and depression or anxiety.
"Beneficial pediatric obesity treatment response yielded enduring health benefits, markedly lowering future morbidity and mortality risks in young adulthood," the authors write.
Several authors disclosed ties to the pharmaceutical industry.
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted January 2025
Read this next
ENDO: Superior Weight Loss Seen With Tirzepatide and Menopausal Hormone Therapy Use
TUESDAY, July 15, 2025 -- In postmenopausal women with overweight or obesity receiving tirzepatide, use of menopausal hormone therapy (MHT) is associated with superior weight loss...
Certain Factors May Predict Weight Fluctuations After GLP-1 Receptor Agonist Treatment
TUESDAY, July 15, 2025 -- For adults with overweight or obesity, certain factors might influence weight loss after taking glucagon-like peptide 1 receptor agonists (GLP-1 RAs)...
ENDO: 1999 to 2020 Saw Significant Uptick in Obesity-Related Cancer Deaths
MONDAY, July 14, 2025 -- From 1999 to 2020, obesity-related cancer mortality increased significantly, according to a study presented at ENDO 2025, the annual meeting of the...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.